Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic Substances
- Sub-Industry: N/A
- Symbol: NASDAQ:NYMX
- CUSIP: N/A
- Web: www.nymox.com
Capitalization:- Market Cap: $203.71 million
- Outstanding Shares: 52,367,000
Average Prices:- 50 Day Moving Avg: $3.67
- 200 Day Moving Avg: $3.87
- 52 Week Range: $2.67 - $5.10
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $180,185.00
- Price / Sales: 1,130.55
- Book Value: ($0.01) per share
- Price / Book: -389.00
Profitability:- EBIDTA: ($11,190,000.00)
- Net Margins: -6,394.07%
- Return on Assets: -683.93%
Debt:- Debt-to-Equity Ratio: -0.92%
- Current Ratio: 0.94%
- Quick Ratio: 0.94%
Misc:- Average Volume: 182,302 shs.
- Beta: 0.86
- Short Ratio: 23.92
Frequently Asked Questions for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
What is Nymox Pharmaceutical Corporation's stock symbol?
Nymox Pharmaceutical Corporation trades on the NASDAQ under the ticker symbol "NYMX."
How were Nymox Pharmaceutical Corporation's earnings last quarter?
When will Nymox Pharmaceutical Corporation make its next earnings announcement?
Who are some of Nymox Pharmaceutical Corporation's key competitors?
Some companies that are related to Nymox Pharmaceutical Corporation include Oxford Immunotec Global PLC (OXFD), Oxford Biomedica (OXBDF), Surmodics (SRDX), UROGEN PHARMA (URGN), Addus HomeCare Corporation (ADUS), NanoString Technologies (NSTG), Sinovac Biotech (SVA), Computer Programs and Systems (CPSI), Syros Pharmaceuticals (SYRS), Corium International (CORI), Flamel Technologies S.A. (AVDL), Rockwell Medical (RMTI), Bellicum Pharmaceuticals (BLCM), Accuray Incorporated (ARAY), Pharming Group (PHGUF), Depomed (DEPO), Teligent (TLGT) and Arbutus Biopharma Corporation (ABUS).
Who owns Nymox Pharmaceutical Corporation stock?
Nymox Pharmaceutical Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (0.57%), Wedbush Securities Inc. (0.47%), TIAA CREF Investment Management LLC (0.15%), Bank of New York Mellon Corp (0.15%), Vanguard Group Inc. (0.14%) and California State Teachers Retirement System (0.10%). View Institutional Ownership Trends for Nymox Pharmaceutical Corporation.
Who bought Nymox Pharmaceutical Corporation stock? Who is buying Nymox Pharmaceutical Corporation stock?
Nymox Pharmaceutical Corporation's stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Vanguard Group Inc., Wedbush Securities Inc., California State Teachers Retirement System, Schwab Charles Investment Management Inc. and Teachers Advisors LLC. View Insider Buying and Selling for Nymox Pharmaceutical Corporation.
How do I buy Nymox Pharmaceutical Corporation stock?
Shares of Nymox Pharmaceutical Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nymox Pharmaceutical Corporation's stock price today?
One share of Nymox Pharmaceutical Corporation stock can currently be purchased for approximately $3.89.
MarketBeat Community Rating for Nymox Pharmaceutical Corporation (NASDAQ NYMX)MarketBeat's community ratings are surveys of what our community members think about Nymox Pharmaceutical Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)Earnings History by Quarter for Nymox Pharmaceutical Corporation (NASDAQ NYMX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/25/2017 | | | | | | | | |
| 11/14/2014 | Q314 | | ($0.02) | | $0.08 million | View | N/A |  |
| 11/13/2013 | Q3 | | ($0.03) | | | View | N/A | |
| 5/15/2013 | Q1 2013 | ($0.05) | ($0.03) | $0.78 million | $0.18 million | View | N/A | |
| 11/14/2012 | Q312 | ($0.06) | ($0.04) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 5.79%
Insider Trades by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/3/2017 | James George Robinson | Director | Buy | 10,000 | $3.73 | $37,300.00 | |
| 8/2/2017 | James George Robinson | Director | Buy | 5,000 | $3.79 | $18,950.00 | |
| 8/1/2017 | James George Robinson | Director | Buy | 15,000 | $3.72 | $55,800.00 | |
| 7/7/2017 | James George Robinson | Director | Buy | 11,500 | $4.00 | $46,000.00 | |
| 7/6/2017 | James George Robinson | Director | Buy | 3,000 | $3.92 | $11,760.00 | |
| 7/5/2017 | James George Robinson | Director | Buy | 5,000 | $3.97 | $19,850.00 | |
| 6/28/2017 | James George Robinson | Director | Buy | 8,500 | $4.09 | $34,765.00 | |
| 6/26/2017 | James George Robinson | Director | Buy | 15,000 | $3.80 | $57,000.00 | |
| 6/21/2017 | James George Robinson | Director | Buy | 15,000 | $3.77 | $56,550.00 | |
| 6/20/2017 | James George Robinson | Director | Buy | 5,000 | $3.76 | $18,800.00 | |
| 6/19/2017 | James George Robinson | Director | Buy | 5,000 | $3.79 | $18,950.00 | |
| 5/30/2017 | James George Robinson | Director | Buy | 54,500 | $3.81 | $207,645.00 | |
| 3/8/2017 | James George Robinson | Director | Buy | 50,000 | $3.59 | $179,500.00 | |
| 8/10/2016 | James George Robinson | Director | Buy | 500 | $2.47 | $1,235.00 | |
| 8/4/2016 | James George Robinson | Director | Buy | 7,000 | $3.41 | $23,870.00 | |
| 7/29/2016 | James George Robinson | Director | Buy | 22,500 | $3.86 | $86,850.00 | |
| 7/20/2016 | James George Robinson | Director | Buy | 10,000 | $3.33 | $33,300.00 | |
| 7/7/2016 | James George Robinson | Director | Buy | 20,000 | $3.28 | $65,600.00 | |
| 6/29/2016 | James George Robinson | Director | Buy | 17,500 | $3.53 | $61,775.00 | |
| 6/24/2016 | James George Robinson | Director | Buy | 22,500 | $2.97 | $66,825.00 | |
| 5/13/2016 | James George Robinson | Director | Buy | 28,010 | $2.31 | $64,703.10 | |
| 5/3/2016 | James George Robinson | Director | Buy | 6,990 | $2.36 | $16,496.40 | |
| 4/29/2016 | James George Robinson | Director | Buy | 15,000 | $2.27 | $34,050.00 | |
| 4/15/2016 | James George Robinson | Director | Buy | 39,500 | $2.39 | $94,405.00 | |
| 4/1/2016 | James George Robinson | Director | Buy | 20,500 | $2.40 | $49,200.00 | |
| 3/24/2016 | James George Robinson | Director | Buy | 40,000 | $2.29 | $91,600.00 | |
| 1/12/2016 | James George Robinson | Director | Buy | 20,000 | $2.44 | $48,800.00 | |
| 1/8/2016 | James George Robinson | Director | Buy | 95,000 | $2.90 | $275,500.00 | |
| 12/30/2015 | James George Robinson | Director | Buy | 5,000 | $3.38 | $16,900.00 | |
| 12/29/2015 | James George Robinson | Director | Buy | 14,000 | $3.55 | $49,700.00 | |
| 12/28/2015 | James George Robinson | Director | Buy | 6,000 | $3.79 | $22,740.00 | |
| 12/23/2015 | James George Robinson | Director | Buy | 29,854 | $3.54 | $105,683.16 | |
| 12/18/2015 | James George Robinson | Director | Buy | 63,334 | $3.56 | $225,469.04 | |
| 12/11/2015 | James George Robinson | Director | Buy | 46,812 | $3.51 | $164,310.12 | |
| 12/4/2015 | James George Robinson | Director | Buy | 110,000 | $3.44 | $378,400.00 | |
| 9/3/2015 | James George Robinson | Director | Buy | 100,000 | $2.25 | $225,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
Latest Headlines for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)
| Source: |
|
| Date | Headline |
|---|
 | Nymox Pharma (NYMX) Says Its MAA For Fexapotide Triflutate was Validated - StreetInsider.com
www.streetinsider.com - September 15 at 7:03 AM |
 | Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
finance.yahoo.com - September 15 at 7:03 AM |
| Nymox Application Validated:
finance.yahoo.com - September 15 at 7:03 AM |
| AUA Meeting in Florida September 16 Postponed Due to Hurricane
finance.yahoo.com - September 12 at 7:40 AM |
| ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
finance.yahoo.com - September 12 at 7:40 AM |
| ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
finance.yahoo.com - September 1 at 6:37 AM |
 | Nymox Pharmaceutical Corporation (NYMX) Lowered to Sell at ValuEngine
www.americanbankingnews.com - August 27 at 1:44 PM |
| Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 9:32 AM |
| Nymox Announces Private Placements of $3 Million
finance.yahoo.com - August 10 at 6:23 AM |
 | Nymox Announces Symposium for Company's BPH Drug at ... - Nasdaq
www.nasdaq.com - August 8 at 2:39 AM |
| Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 10,000 Shares
www.americanbankingnews.com - August 4 at 9:00 PM |
| Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Buys 5,000 Shares of Stock
www.americanbankingnews.com - August 4 at 9:00 PM |
| ETFs with exposure to Nymox Pharmaceutical Corp. : August 4, 2017
finance.yahoo.com - August 4 at 6:32 AM |
| Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson Acquires 15,000 Shares
www.americanbankingnews.com - August 1 at 8:21 PM |
| Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Buys 11,500 Shares
www.americanbankingnews.com - July 7 at 9:03 PM |
| Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 5,000 Shares
www.americanbankingnews.com - July 7 at 9:02 PM |
| Insider Buying: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director Acquires 3,000 Shares of Stock
www.americanbankingnews.com - July 7 at 9:02 PM |
 | Commit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options
www.thestreet.com - July 6 at 7:37 AM |
| ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
finance.yahoo.com - July 5 at 9:08 AM |
| Nymox Pharmaceutical Corporation (NYMX) Director James George Robinson Acquires 8,500 Shares
www.americanbankingnews.com - June 29 at 8:36 PM |
| Insider Buying: Nymox Pharmaceutical Corporation (NYMX) Director Purchases 15,000 Shares of Stock
www.americanbankingnews.com - June 26 at 7:18 PM |
| Insider Buying: Nymox Pharmaceutical Corporation (NYMX) Director Acquires 5,000 Shares of Stock
www.americanbankingnews.com - June 21 at 10:46 PM |
| James George Robinson Buys 5,000 Shares of Nymox Pharmaceutical Corporation (NYMX) Stock
www.americanbankingnews.com - June 21 at 10:46 PM |
| James George Robinson Purchases 15,000 Shares of Nymox Pharmaceutical Corporation (NYMX) Stock
www.americanbankingnews.com - June 21 at 8:04 PM |
| Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical Trials
finance.yahoo.com - May 31 at 7:18 PM |
| Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Purchases 54,500 Shares
www.americanbankingnews.com - May 31 at 4:26 PM |
 | Sexual Function Improves in First-Line Patients Given Fexapotide Treatment in Nymox U.S. BPH Long-Term Clinical ... - GlobeNewswire (press release)
globenewswire.com - May 31 at 11:29 AM |
| Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 10:18 AM |
| Nymox reports 1Q loss
finance.yahoo.com - May 16 at 10:05 AM |
| NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 ...
globenewswire.com - May 12 at 12:29 AM |
 | NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT
feeds.benzinga.com - May 10 at 11:37 AM |
| NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT
finance.yahoo.com - May 8 at 12:13 PM |
| Nymox Pharmaceutical (NYMX) Earning Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 4 at 12:08 PM |
| NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe - GlobeNewswire (press release)
globenewswire.com - May 3 at 8:06 PM |
| NYMOX Files For Marketing Approval For Fexapotide Triflutate in Europe
finance.yahoo.com - May 3 at 8:06 PM |
| Somewhat Favorable News Coverage Likely to Affect Nymox Pharmaceutical (NYMX) Stock Price
www.americanbankingnews.com - April 23 at 10:44 PM |
| Nymox Pharmaceutical (NYMX) Earning Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 21 at 12:33 AM |
| Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
finance.yahoo.com - April 7 at 11:39 AM |
| Pacific Biosciences of California and Nymox Pharmaceutical Move Up On Bullish Product Environments
finance.yahoo.com - March 30 at 7:15 PM |
| Nymox Pharmaceutical Co. (NYMX) Director James George Robinson Purchases 50,000 Shares
www.americanbankingnews.com - March 29 at 10:34 PM |
| BUZZ-US STOCKS ON THE MOVE-Vertex Pharma, Morgan Stanley, F5, Exar, Tonix Pharma, Vertex - Nasdaq
www.nasdaq.com - March 29 at 7:38 PM |
| Nymox Provides Update on Fexapotide Development
finance.yahoo.com - March 29 at 7:38 PM |
| 10:46 am Nymox Pharma provides update, says now expects to submit its initial filing seeking approval for Fexapotide Triflutate in the next few weeks
finance.yahoo.com - March 29 at 7:38 PM |
| IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - March 1 at 10:26 AM |
| Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company
finance.yahoo.com - March 1 at 10:26 AM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
finance.yahoo.com - March 1 at 10:26 AM |
 | 5 Biohealth Stocks Rising 10% or More on News
247wallst.com - March 1 at 10:26 AM |
| Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress
www.thestreet.com - March 1 at 10:26 AM |
| Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success
www.thestreet.com - March 1 at 10:26 AM |
| Why Nymox Pharma (NYMX) Closed the Day Up 83%
finance.yahoo.com - March 1 at 10:26 AM |
Nymox Pharmaceutical Corporation (NYMX) Chart for Monday, September, 25, 2017
